Abstract：Objective To explore the clinical efficacy of Losartan in the treatment of maintenance hemodialysis(MHD)patients with chronic kidney disease(CKD)and its effect on iron metabolism and inflammatory factors.Methods A total of 50 patients with CKD who received maintenance hemodialysis in Xiaolan people′s Hospital of Zhongshan City from June 2019 to June 2020 were selected as the research objects.They were randomly divided into the treatment group and the control group,with 25 cases in each group.The treatment group was treated with Losartan,while the control group was treated with conventional renal anemia The changes of C-reactive protein(CRP),interleukin-6(IL-6),ferritin(SF)and transferin saturation(TSAT)were observed.Results After 3 months of treatment,the total clinical effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).There were no significant differences in CRP,IL-6,TSAT and SF between the two groups before treatment and one month after treatment(P>0.05).After 2 and 3 months of treatment,CRP,IL-6 and SF in the treatment group were lower than those in the control group,and TSAT was higher than that in the control group,with statistical significances(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Losartan in the treatment of maintenance hemodialysis patients with CKD can effectively improve the symptoms of anemia,relieve the micro inflammatory state,and has high safety.
张文彬；池向耿；陈艳转；禤杏华；蔡琪. 罗沙司他治疗慢性肾脏病维持性血液透析患者的临床效果及对铁代谢、炎症因子的影响[J]. 中国当代医药, 2021, 28(27): 69-72.
ZHANG Wen-bin；CHI Xiang-geng；CHEN Yan-zhuan；XUAN Xing-hua；CAI Qi. Clinical effect of Losartan on maintenance hemodialysis and its effect on iron metabolism and inflammatory factors. 中国当代医药, 2021, 28(27): 69-72.
京公网安备 11010502046607号